Valuation: Polaris Group

Market Cap 10.4B 322M 283M 263M 242M 453M 31.11B 463M 3.14B 1.22B 15.22B 1.21B 1.18B 52.8B P/E 2024
-13.6x
P/E 2025 -6.1x
Enterprise Value 10.92B 338M 297M 276M 254M 476M 32.66B 486M 3.29B 1.28B 15.97B 1.27B 1.24B 55.42B EV / Sales 2024
318x
EV / Sales 2025 603x
Free-Float
37.54%
Yield 2024 *
-
Yield 2025 -
1 day+0.41%
1 week-3.20%
Current month-10.70%
1 month-8.33%
3 months-34.95%
6 months-60.84%
Current year-61.09%
1 week 11.9
Extreme 11.9
12.75
1 month 11.9
Extreme 11.9
14.35
Current year 11.9
Extreme 11.9
35.95
1 year 11.9
Extreme 11.9
44.55
3 years 11.9
Extreme 11.9
91.1
5 years 11.9
Extreme 11.9
232
10 years 9.5
Extreme 9.5
232
Manager TitleAgeSince
Director of Finance/CFO - 2019-02-28
Chief Operating Officer - 2019-01-31
Chief Executive Officer - 2014-04-30
Director TitleAgeSince
Chairman 64 2014-11-23
Director/Board Member - 2020-02-24
Director/Board Member - 2020-01-02
Change 5-day change 1-year change 3-year change Capi.($)
+0.41%-3.20%-67.56%-86.11% 319M
+1.08%-6.74%-2.31%+10.45% 46.06B
+3.13%+2.34%+393.21%+605.08% 38.91B
+2.14%+4.98%+10.55%+65.45% 35.57B
+4.43%+0.25%+10.64%-9.17% 33.13B
+1.23%-1.99%-0.05%+30.76% 26.42B
+0.29%-5.92% - - 16.61B
+14.71%+14.47%+26.81%+146.99% 15.08B
-6.32%-4.59%+4.36%+8.22% 14.08B
+1.82%-1.02%+5.46%-30.74% 12.81B
Average +1.96%-1.99%+42.35%+82.32% 23.9B
Weighted average by Cap. +1.91%-2.47%+73.90%+129.39%

Financials

2024 2025
Net sales 107M 3.31M 2.91M 2.7M 2.49M 4.66M 320M 4.76M 32.27M 12.59M 156M 12.43M 12.17M 543M 40.6M 1.26M 1.1M 1.03M 943K 1.77M 121M 1.81M 12.24M 4.78M 59.38M 4.72M 4.62M 206M
Net income -2.5B -77.5M -68.02M -63.21M -58.13M -109M -7.48B -111M -755M -294M -3.66B -291M -285M -12.7B -3.93B -122M -107M -99.19M -91.22M -171M -11.74B -175M -1.18B -462M -5.74B -456M -447M -19.93B
Net Debt 9.19M 285K 250K 232K 214K 400K 27.48M 409K 2.77M 1.08M 13.44M 1.07M 1.05M 46.64M 517M 16.01M 14.05M 13.06M 12.01M 22.51M 1.55B 22.99M 156M 60.81M 756M 60.06M 58.79M 2.62B
Logo Polaris Group
The Polaris Group, LLC is a Cayman Islands-based company, which is primarily engaged in biotechnology services, drug testing, contract development and manufacturing services and research, development, manufacture and sales of new drugs. The Company’s core research is ADI-PEG 20, which is undergoing human clinical trials for various cancer indications. The ADI-PEG 20 is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia, and others. ADI-PEG 20 is a biological drug produced by coupling arginine deiminase and polyethylene glycol with a molecular weight of 20,000.
Employees
-
Date Price Change Volume
26-07-23 NT$12.10 +0.41% 1,135,739
26-07-22 NT$12.05 -2.82% 1,810,418
26-07-21 NT$12.40 +0.81% 671,097
26-07-20 NT$12.30 +0.82% 853,917
26-07-17 NT$12.20 -4.69% 1,333,703
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. 6550 Stock